Requires health insurance policies to offer full coverage for annual testing for ovarian cancer; requires certain health care providers offer annual testing for ovarian cancer.
This bill would require a broad range of New York health insurance policies to provide full coverage for annual ovarian cancer testing for people at high risk of developing the disease. The mandate applies to individual, group, blanket, and certain nonprofit health plans, and it specifies that covered testing may include FDA-approved tests, transvaginal ultrasound, pelvic exams, and other exams, even when the patient is not yet showing signs or symptoms. The bill also states that this coverage cannot be subject to deductibles or coinsurance, meaning the insurer must bear the cost.
In addition to insurance coverage changes, the bill amends the social services law so Medicaid covers annual ovarian cancer testing for at-risk individuals. It also adds a new public health law section requiring primary care providers such as physicians, physician assistants, nurse practitioners, and midwives to ask screening questions, offer ovarian cancer testing when signs, symptoms, or suspicion are present, and provide patient education materials. The Department of Health would be required to develop and distribute informational pamphlets, and the offering of testing must be culturally and linguistically appropriate.
The bill would expand mandated health insurance benefits in New York and add a Medicaid coverage requirement for ovarian cancer testing, affecting insurers, health maintenance organizations, hospital and medical service corporations, and public benefit programs. It would also create a new provider-facing obligation in the public health law for primary care practitioners to screen for possible ovarian cancer and offer testing when appropriate, while preserving existing scope-of-practice rules. The bill would apply to policies issued, renewed, reissued, modified, or amended on or after its effective date.
Based on the bill text and available context, the measure appears to be introduced in support of expanded cancer screening and earlier detection, with no recorded committee debate or votes showing opposition or amendment activity. The overall tone is preventive and patient-protective, emphasizing access, education, and removal of cost barriers for high-risk patients. Because no transcripts or voting history are available, there is no documented formal sentiment from committee members or floor action beyond the bill’s pro-screening framing.
The main potential points of contention are the cost and scope of the insurance mandate, especially the requirement that insurers cover annual testing without deductibles or coinsurance and even before symptoms appear. Insurers may view the bill as an expanded benefit mandate that could increase premiums or utilization, while supporters are likely to argue that early detection for high-risk patients justifies the added cost. Another possible issue is the provider requirement to ask screening questions and offer testing, which could raise implementation concerns for primary care practices, though the bill attempts to limit this by tying testing to signs, symptoms, or clinical suspicion and by preserving professional judgment and scope of practice.